Takeda, Sanofi To Partner For Diabetes Drug Sales In China
This article was originally published in PharmAsia News
Takeda Pharmaceutical and Sanofi Group plan a partnership aimed at increasing lifestyle drug sales in China, beginning this fiscal year with the Japan drug maker's Nesina (alogliptin) diabetes treatment.
You may also be interested in...
With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.
Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.
RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.